Tendons are highly specialized connective tissues responsible for transmitting mechanical forces from muscle to bone. Their dense collagen structure and relatively limited vascularization contribute to their mechanical strength but also result in a reduced regenerative capacity following injury. As a result, tendon healing represents a complex and often prolonged biological process that has been extensively studied in experimental and preclinical research settings.
Tendon repair involves a coordinated sequence of cellular and molecular events, including inflammatory signaling, fibroblast proliferation, extracellular matrix synthesis, angiogenesis, and long-term tissue remodeling. Disruption of any of these phases may impair structural organization and mechanical integrity. For this reason, research has focused on identifying molecular regulators capable of modulating these processes at the cellular level. Among the biologically active peptides investigated in this context, BPC-157 has received particular attention in preclinical tendon research.
BPC-157 is a stable pentadecapeptide originally identified in human gastric juice and subsequently examined in various experimental models of tissue injury. In animal studies, BPC-157 has been evaluated for its interaction with cellular signaling pathways relevant to connective tissue repair, including those involved in fibroblast activity, angiogenesis, and growth factor signaling. Tendon fibroblasts, which play a central role in collagen production and matrix organization, represent a key cellular target in tendon healing research.
A pivotal in vitro study by Chang et al. investigated the effects of BPC-157 on fibroblasts isolated from rat Achilles tendons. Using cDNA microarray analysis, the researchers identified growth hormone receptor expression as one of the most significantly upregulated genes following exposure to BPC-157. Subsequent analyses confirmed that BPC-157 increased growth hormone receptor expression at both the mRNA and protein levels in a time- and dose-dependent manner. When growth hormone was added to BPC-157-treated fibroblasts, cellular proliferation increased significantly, accompanied by elevated expression of proliferating cell nuclear antigen. Activation of the Janus kinase 2 signaling pathway further supported the involvement of canonical growth hormone receptor signaling in this response. These findings suggest that BPC-157 may modulate tendon fibroblast responsiveness to endogenous growth signals under experimental conditions.
Beyond direct cellular effects, tendon healing is closely linked to angiogenic processes. Although mature tendons are relatively hypovascular, transient neovascularization is a recognized component of early repair phases, facilitating nutrient delivery and cellular migration. Preclinical studies have explored the interaction between BPC-157 and angiogenic signaling pathways, including those involving nitric oxide, vascular endothelial growth factor, and focal adhesion kinase. These pathways are known to influence endothelial function, microvascular stability, and tissue perfusion during repair.
Comparative analyses of angiogenic growth factors and peptide-based modulators have highlighted notable differences in experimental models. While classical growth factors such as VEGF, FGF, and EGF demonstrate angiogenic activity, their effects in tendon healing models are often dependent on delivery systems, local administration, and experimental conditions. In contrast, BPC-157 has been reported to exert consistent biological activity across multiple models of connective tissue injury, including tendons, ligaments, muscles, and bone, using comparable experimental protocols. Importantly, these observations remain confined to laboratory and animal studies and are interpreted within a mechanistic research framework.
Extracellular matrix remodeling represents another critical aspect of tendon repair. Fibroblasts regulate the synthesis and alignment of collagen fibers, primarily type I collagen, which determines the mechanical properties of healed tendon tissue. Experimental investigations indicate that peptide-mediated modulation of fibroblast activity may influence matrix organization, collagen deposition, and the balance between synthesis and degradation. In tendon injury models, BPC-157 has been examined for its effects on structural restoration and biomechanical outcomes, with analyses focusing on tissue morphology rather than clinical endpoints.
Inflammatory regulation also plays a decisive role in tendon healing. Acute inflammation initiates repair, but prolonged or dysregulated inflammatory responses can impair matrix organization and contribute to chronic degeneration. Preclinical research suggests that BPC-157 interacts with inflammatory signaling pathways, potentially influencing cytokine balance and cellular responses during early repair phases. These findings further underscore the peptide’s relevance as a research tool for studying inflammation-repair interactions in tendon biology.
From a safety standpoint, available data from animal and in vitro studies report no significant acute toxicity associated with BPC-157 at experimentally tested concentrations. However, these findings are limited to preclinical research and do not constitute evidence of safety or efficacy in humans. To date, there are no large-scale, controlled clinical trials establishing clinical applications for tendon healing.
In conclusion, tendon healing is governed by tightly regulated biological mechanisms involving fibroblast proliferation, angiogenesis, extracellular matrix remodeling, and inflammatory control. Preclinical research on BPC-157 provides valuable insights into how peptide-mediated modulation of growth factor signaling and vascular responses may influence tendon repair processes at the cellular and tissue levels. These findings contribute to a growing body of experimental knowledge and remain strictly within the domain of basic and translational research.
References
Chang C-H., Tsai W-C., Hsu Y-H., Su Pang J-H. (2014). Pentadecapeptide BPC-157 increases growth hormone receptor expression in tendon fibroblasts. Molecules, 19(11), 19066–19077.
Seiwerth S., Rucman R., Turkovič B., Sever M., Kliček R., Radic B., Drmič D., et al. (2018). BPC-157 and standard angiogenic growth factors: implications for gastrointestinal and musculoskeletal tissue healing. Current Pharmaceutical Design, 24(18), 1972–1989.Sharma P., Maffulli N. (2006). Tendon injury and healing: molecular and cellular mechanisms. Journal of Bone and Joint Surgery.